Avisi Technologies: $10.7 Million Series A Raised To Advance Novel Glaucoma Device Development
By Amit Chowdhry ● Today at 8:12 AM
Avisi Technologies, a clinical-stage ophthalmic medical device company, announced the closing of a $10.7 million Series A financing round to advance development of its investigational VisiPlate glaucoma treatment and support its pivotal SAPPHIRE clinical trial. The round was led by MedVenture Partners, with participation from new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive. Existing investors, including Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments, also participated. As part of the financing, Justin Fukuyama, MS, MBA, Partner at MedVenture Partners, has joined Avisi’s Board of Directors.